DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Venous Thromboembolism, Atrial Fibrillation, and Acute Coronary Syndrome (Novel Oral Anticoagulants – Evolving Treatments ) | Physician & Payer Forum | China | 2014
Warfarin has been the mainstay of anticoagulation therapy for the past several decades, but difficulties associated with its use and the clinical management of patients have prompted the…
Prostate Cancer (First-Line [Chemotherapy-Naive] Metastatic Castrate-Resistant) | Decision Base | US/EU | 2014
As Abiraterone and Enzalutamide Gain Traction in the Market, What Key Attributes Do Oncologists and Payers Say Will Differentiate Emerging Therapies? The first-line (chemotherapy-naive)…
Prostate Cancer (First-Line – Chemotherapy-Naive – Metastatic Castrate-Resistant) | DecisionBase | US/EU | 2014
As Abiraterone and Enzalutamide Gain Traction in the Market, What Key Attributes Do Oncologists and Payers Say Will Differentiate Emerging Therapies? The first-line (chemotherapy-naive)…
The Impact of LATAM – Payer Policy on Prescribing in Non-Hodgkin’s Lymphoma and Multiple Myeloma | Physician & Payer Forum | Brazil and Mexico | 2014
Improved patient access to specialized medical care and increased use of target therapies in oncology are expanding the multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL) markets in Brazil…
Type 2 Diabetes Inadequately Controlled with Diet and Exercise (First-Line Drug Treatment) | Decision Base | US/EU | 2014
When Metformin Is Not a Therapeutic Option, What Treatments Hold Greatest Appeal to Physicians and Payers? Affecting more than 30 million people in the United States alone, type 2 diabetes is a…
Type 2 Diabetes Inadequately Controlled with Diet and Exercise (First-Line Drug Treatment) | Decision Base | US/EU | 2014
When Metformin Is Not a Therapeutic Option, What Treatments Hold Greatest Appeal to Physicians and Payers? Affecting more than 30 million people in the United States alone, type 2 diabetes is a…
Patient Access to High-Cost Therapies for CML in China: How Are Payers and Physicians Shaping This Crowded and Changing Market? | Physician & Payer Forum | China | 2014
Chronic myeloid leukemia (CML) in China presents a huge challenge for healthcare providers but is a considerable opportunity for drug manufacturers. The launch of Novartis’s Glivec (imatinib), an…
